Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japanese Pharma Companies Speed Up Mergers And Acquisitions In Growing Biopharmaceutical Arena

This article was originally published in PharmAsia News

Executive Summary

Major Japanese pharmaceutical companies have been in an uphill battle to develop new drugs, and as the biopharmaceutical industry captures attention, they are increasingly turning to mergers and acquisitions overseas with leading international biopharmaceutical companies. Eisai bought an American biopharma venture for ¥430 billion. Last year, Takeda set up an antibody research facility in San Francisco, where many of America's biopharma companies are concentrated. On Feb. 4, Takeda announced a buyout of Amgen's wholly-owned business unit in Japan. Through the purchase, Takeda obtained licensing rights for the sole development and marketing of 13 new drugs in Japan, including cancer drug AMG706 (motesanib) and other antibody drugs. It is expected that the buyout will speed up Takeda's presence in this growing area. (Click for more-Japanese language

You may also be interested in...

Towa Plans 10 Launches In December 2020

After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well. 

Pfizer Confirms EU Pegfilgrastim Launch Plans

Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.

Oxford/AZ’s COVID-19 Vaccine Cuts Virus Spread By 60%

Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts